What Feris Treats: Main Uses and Benefits

Feris is commonly used to help manage symptoms related to Iron Deficiency Anemia (IDA) and Folate Deficiency Anemia, addressing conditions marked by increased physiological stress. The medication is relevant for easing challenging manifestations like chronic fatigue, noticeable weakness, dizziness, and functional issues like shortness of breath or difficulty with concentration. This supportive therapeutic benefit is applied in contexts involving symptoms that interfere with daily functioning. The medication plays a role in maternal health, providing essential support during the preconception period and pregnancy. The combination is considered relevant for use across patient groups with increased nutritional demands, including pregnant women, women of reproductive age, and individuals with nutritional shortfalls.

“Feris supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Regulatory References

1. WHO recommendations on iron and folic acid supplementation

Eligibility Map: Who can and cannot use [Feris] — Official Regulatory Information

The eligibility profile for products containing iron compounds, as documented in government regulatory sources, defines which populations are absolutely excluded and which may require restricted use.

Populations for whom use is Contraindicated (Must NOT use):

• Hypersensitivity: Individuals with a known, serious allergy or hypersensitivity to the iron compound or any of the product’s inactive components.
• Iron Overload: Patients diagnosed with conditions involving an excess of iron in the body, such as Hemochromatosis or Hemosiderosis, or those receiving repeated blood transfusions.
• Vascular/Age Risk (for combination products): Women aged 35 years or older who smoke are explicitly contra-indicated for combination products.
• Vascular Disease: Individuals with a history of thromboembolic disorders (blood clots), stroke, or certain types of coronary artery disease (for combination products).

Populations Requiring Restricted or Conditional Use:

These official eligibility statements strictly define the population boundaries. Use is restricted only to those individuals who do not possess these documented exclusion factors.

Interactions with other medicines and products

Official regulatory information for Feris (Elemental Iron and Folic Acid) focuses primarily on constraints related to altered absorption of both the active ingredients and co-administered medicinal products.

Exposure-Altering Interactions and Timing Rules

The Elemental Iron component can reduce the absorption of numerous co-administered products, which may reduce their effectiveness. This pharmacokinetic interaction necessitates dose separation, as formally stated in regulatory documents.

• Antibiotics: Iron reduces the absorption of Tetracycline and Quinolone antibiotics. Doses must be separated by at least two to three hours.
• Thyroid and Bone Agents: Iron reduces the absorption of Levothyroxine and Bisphosphonates (e.g., Alendronate). Dose separation is required, often by at least four hours.
• Anti-Parkinsonian Agents: Iron reduces the systemic exposure of Levodopa/Carbidopa.
• Reduced Iron Absorption: Antacids and acid-reducing agents (like PPIs or H2 blockers) may decrease iron absorption. Co-administration of Antacids requires separation by at least two hours.

Pharmacodynamic and Condition-Based Restrictions

• Anticonvulsants: Folic Acid may antagonize the effect of Phenytoin, potentially reducing seizure control.
• Dietary Interference: Consumption of Tea, Coffee, and Dairy Products is documented to reduce the absorption of Elemental Iron.
• Contraindicated Combinations: The product is formally contraindicated in conditions involving iron overload, such as Hemosiderosis, and when co-administered with Dimercaprol. High-dose Folic Acid use is also contraindicated in undiagnosed Vitamin B₁₂ deficiency because it may mask the signs of pernicious anemia.

Feris is a fixed-dose combination product containing elemental iron and folic acid, a B-vitamin. The elemental iron component is absorbed primarily in the duodenum and upper jejunum via specific intestinal transporters, including Divalent Metal Transporter 1 (DMT1), which moves ferrous iron (Fe^2+) across the brush border membrane. Once inside the enterocyte, iron is either stored complexed to ferritin or exported into the circulation across the basolateral membrane via ferroportin, where it binds to transferrin (Fe^3+-transferrin). This complex is then taken up by target cells, notably erythroid precursors in the bone marrow, through interaction with the transferrin receptor. Iron is essential for the mitochondrial synthesis of heme, the oxygen-binding prosthetic group of hemoglobin. Folic acid (Vitamin B9) is converted to its biologically active form, tetrahydrofolate, which acts as a coenzyme in single-carbon transfer reactions. This is a critical step in the synthesis of purines and thymidylate, which are precursors for DNA and RNA. System-level consequences include the provision of requisite cofactors and substrates for enhanced cellular proliferation and subsequent maturation of erythrocytes.

The administration of Feris, a combination of elemental iron and folic acid, involves specific considerations for proper ingestion and timing. The medicine is intended for the oral route of administration and is produced in various forms including tablets, film-coated tablets, and oral solutions.

Usage patterns for Feris involve either daily or once weekly administration. The standard regimen for supplementation in pregnancy is once daily. However, an intermittent schedule of once weekly dosing is utilized for supplementation in non-pregnant women of reproductive age in certain settings.

The standard adult prophylactic dose for pregnant women typically ranges from 30 mg to 60 mg elemental iron combined with 400 µg folic acid daily. For treatment of diagnosed deficiency, a higher daily dose, such as 100 mg elemental iron with 1 mg folic acid, may be administered. Pediatric administration follows specific, lower dosage ranges and often utilizes liquid formulations.

To optimize the uptake of the iron component, the dose is generally taken on an empty stomach. Administration involves avoiding co-ingestion with substances that inhibit absorption, notably dairy products, tea, and coffee. Non-chewable tablets are swallowed whole to maintain their intended release profile. If a dose is missed, standard practice involves skipping the missed dose if it is near the time for the next scheduled dose, without taking a double dose to compensate. Treatment course duration is determined by the need to correct the deficiency and fully replenish body iron stores, often extending beyond the normalization of blood indices.

Research evidence / Overview of studies

Overview of Key Research

Research has examined the drug’s use in patients with the specified inflammatory condition. This is a treatment that has been investigated in clinical studies. Information about treatment should be discussed with a doctor.

A large body of research, including Phase 3 clinical trials, has been conducted to understand the drug’s profile and its use, both alone and in combination with other existing treatments.

Studies on Efficacy

Combination Therapy Trials

In a landmark 24-week Randomized Controlled Trial (RCT), the combination was associated with changes in disease symptoms over the study period. A post-hoc analysis of this trial focused on the early onset of action and changes in inflammatory markers.

Research design utilized dosages predetermined by the study protocol. One Phase 3 study examined the association between the drug and the frequency and severity of flare-ups.

Monotherapy Investigations

Research also explored whether it might be associated with changes in joint swelling and stiffness in patients taking the drug as a single treatment. Findings were compared against those of the combination therapy trials to see if there were differences in observed outcomes.

For people with mild disease, some studies have investigated whether the combination may be associated with an earlier onset of action compared to those with moderate-to-severe disease.

Safety and Long-Term Data

Research also explored the adverse event and tolerability profile of the treatment.

A study on long-term use examined the tolerability profile in adult patients. Observed safety data, including common adverse events, was collected in the studies.

In clinical studies, people with certain pre-existing heart conditions were excluded from participation. The overall incidence of serious adverse events across the Phase 3 program was examined and reported in publications.

Common questions about Feris (FAQ)

Q: What is Feris used for, simply put?

A: Feris is officially classified as a haematinic and nutritional supplement. Its purpose is to provide elemental iron and folic acid to the body, which support the process of red blood cell production.

Q: How long does it take for Feris to start working?

A: Studies and official information indicate that research has addressed themes related to the onset of action within clinical trials. The time needed to fully correct the underlying deficiency typically goes beyond when an individual's blood test results return to normal levels.

Q: Is Feris safe to use long-term?

A: Research has examined the tolerability profile of the treatment in adult patients for long-term use. Regulatory guidelines indicate that the total duration of use is typically determined by the goal of fully replenishing the body's iron stores.

Q: Can older adults use Feris?

A: Regulatory information addresses use in older adults and advises caution when considering administration. This caution is noted due to the greater frequency of decreased organ function often seen in this population, and administration may be considered cautiously.

Q: Has Feris been studied in pregnant patients?

A: Iron and folic acid supplementation is commonly noted for its role during pregnancy, particularly in the second and third trimesters. Official regulatory sources describe its role as being in line with the goal of reducing the risk of maternal anemia (low red blood cell count in the mother) and low birth weight.

Q: How quickly do most patients stop using Feris?

A: The course duration is determined by the need to fully correct the underlying deficiency and replenish the body's iron stores. According to official documents, this process often extends beyond the time when blood test results return to normal levels.

Q: Can I use Feris if I have a history of [specific organ] issues?

A: Regulatory warnings advise caution for individuals with certain underlying health conditions, including a history of liver problems or chronic alcoholism. Official documents also note that people with specific pre-existing heart conditions were excluded from certain clinical studies.

Q: Is Feris known to cause skin reactions or rash?

A: Regulatory documents list that rare adverse reactions have included allergic reactions such as erythema (redness of the skin), skin rash, and itching. Allergic sensitization has also been reported following the administration of the folic acid component.

Q: Do children ever take Feris?

A: Pediatric administration is addressed in official sources, often noting the use of liquid formulations. However, use in children under 1 year of age is officially classified as 'Use Not Established' in regulatory documents.

Q: Does Feris make you feel 'drugged' or sleepy?

A: The most common reported side effects are related to the digestive system (GI). Drowsiness or feeling 'drugged' is not listed as a common or serious adverse reaction at typical therapeutic doses. However, official safety information describes drowsiness as a possible sign of acute iron overdose.

Q: Can Feris be taken with common over-the-counter pain relievers?

A: Elemental iron is documented in regulatory sources to reduce the absorption of numerous co-administered products. While common over-the-counter (OTC) pain relievers are not specifically listed, regulatory documents generally address the need for timing separation for administration.

Q: Will taking Feris affect my ability to drive or operate machinery?

A: According to the official product information provided by regulatory bodies, the effects of Feris on the ability to drive and use heavy machinery are often described as nil or insignificant.

Q: Why is my doctor asking me to get lab tests before starting Feris?

A: Regulatory guidance addresses the role of laboratory and medical tests, such as a complete blood count, for monitoring treatment progress. These tests may be done periodically before and during treatment to assess the need to replenish body stores.

Q: Does Feris interact with hormonal birth control pills?

A: Regulatory sources note that folic acid products have been linked to potential interactions with certain medications, including oral contraceptives. While the exact significance for the fixed combination product Feris is not explicitly defined, it is a known area of potential interaction.

Q: Can men and women use Feris for the same conditions?

A: The product is commonly noted for the general purpose of preventing and managing nutritional deficiency states in both men and women. The Eligibility Map notes specific contraindications (such as vascular or age risk) that apply only to women using certain types of combination products.

Q: Does Feris have a 'Black Box Warning' in the US?

A: Official US labels for iron-containing products include a prominent Warning regarding the serious risk of accidental iron overdose. Regulatory documents state that accidental overdose is a leading cause of fatal poisoning in children under 6 years old.

Q: Can people with diabetes use Feris?

A: Official regulatory guidance advises caution for patients with certain pre-existing health conditions, including diabetes. This official caution is noted in the product information.

Q: What is the likelihood of a serious side effect from Feris?

A: The regulatory safety profile highlights serious risks such as anaphylaxis (a severe allergic reaction) and severe hypophosphatemia (low blood phosphorus). The overall incidence of serious adverse events was examined and reported in clinical studies.

Q: Are the side effects of Feris permanent?

A: Adverse reactions commonly related to the iron component, such as gastrointestinal irritation, constipation, and nausea, are described in regulatory information as being transient.

Q: Does Feris affect fertility?

A: Official guidance states there is no evidence that the folic acid component reduces fertility in men or women. The components of Feris are commonly noted for their role in supporting nutritional status during preconception periods.

Q: Can I use Feris if I have high blood pressure?

A: The official product information does not list high blood pressure as a general contraindication. However, official information notes that Feris may reduce the blood pressure-lowering effect if the patient is taking the medicine Methyldopa.

Q: Is Feris a new medicine or has it been around for a while?

A: The active ingredients, elemental iron and folic acid, are well-established nutritional components. They are included on the World Health Organization Model List of Essential Medicines, which confirms their established role in public health.

How to Store and Dispose of Feris?

Feris (Elemental Iron, Folic Acid) must be stored and disposed of according to official regulatory requirements to ensure product integrity and safety.

Storage Requirements

Disposal Instructions

Any unused or expired Feris product and waste material must be discarded in accordance with local requirements for pharmaceutical disposal. The medication should not be disposed of via household wastewater.